AR094027A1 - Formulaciones topicas que contienen pidotimod - Google Patents
Formulaciones topicas que contienen pidotimodInfo
- Publication number
- AR094027A1 AR094027A1 ARP130104757A ARP130104757A AR094027A1 AR 094027 A1 AR094027 A1 AR 094027A1 AR P130104757 A ARP130104757 A AR P130104757A AR P130104757 A ARP130104757 A AR P130104757A AR 094027 A1 AR094027 A1 AR 094027A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation according
- vitamin
- topical formulation
- topical
- topical formulations
- Prior art date
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 title abstract 8
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title abstract 2
- 229960001163 pidotimod Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract 2
- 229930003316 Vitamin D Natural products 0.000 abstract 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 2
- 229960001334 corticosteroids Drugs 0.000 abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract 2
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 2
- 235000019155 vitamin A Nutrition 0.000 abstract 2
- 239000011719 vitamin A Substances 0.000 abstract 2
- 235000019166 vitamin D Nutrition 0.000 abstract 2
- 239000011710 vitamin D Substances 0.000 abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 2
- 229940045997 vitamin a Drugs 0.000 abstract 2
- 229940046008 vitamin d Drugs 0.000 abstract 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 abstract 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 abstract 1
- 229960005339 acitretin Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960002964 adalimumab Drugs 0.000 abstract 1
- 229960002916 adapalene Drugs 0.000 abstract 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 abstract 1
- 229960002459 alefacept Drugs 0.000 abstract 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 abstract 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
- 229960002170 azathioprine Drugs 0.000 abstract 1
- 229960002938 bexarotene Drugs 0.000 abstract 1
- 229960002882 calcipotriol Drugs 0.000 abstract 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 abstract 1
- 229960005084 calcitriol Drugs 0.000 abstract 1
- 235000020964 calcitriol Nutrition 0.000 abstract 1
- 239000011612 calcitriol Substances 0.000 abstract 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 229960002199 etretinate Drugs 0.000 abstract 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 abstract 1
- 229960002598 fumaric acid Drugs 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 229960000598 infliximab Drugs 0.000 abstract 1
- 229960005280 isotretinoin Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 abstract 1
- 229960005330 pimecrolimus Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229960004907 tacalcitol Drugs 0.000 abstract 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 abstract 1
- 229960001967 tacrolimus Drugs 0.000 abstract 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1
- 229960000565 tazarotene Drugs 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 229960001727 tretinoin Drugs 0.000 abstract 1
- 229960003824 ustekinumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Formulaciones tópicas que contienen pidotimod, o una sal fisiológicamente aceptable del mismo, junto con al menos un excipiente farmacéuticamente aceptable; tales formulaciones tópicas, que son preferentemente semi-sólidas o líquidas, están principalmente destinadas al tratamiento de psoriasis y/o dermatitis atópica. Reivindicación 7: Una formulación tópica de acuerdo con la reivindicación 6, caracterizada en que dicho al menos un principio activo adicional es seleccionado de agentes inmunosupresores, Vitamina D y análogos, compuestos relacionados con la Vitamina A, corticosteroides, compuestos biológicos. Reivindicación 8: Una formulación tópica de acuerdo con la reivindicación 7, caracterizada en que dicho al menos un agente inmunosupresor es seleccionado de: metotrexato, azatioprina, ciclosporina, ácido fumárico, tacrolimus o pimecrolimus y corticosteroides. Reivindicación 9: Una formulación tópica de acuerdo con la reivindicación 7, caracterizada en que dicho al menos un análogo de Vitamina D es seleccionado de calcitriol, calcipotriol y tacalcitol. Reivindicación 10: Una formulación tópica de acuerdo con la reivindicación 7, caracterizada en que dicho al menos un compuesto relacionado con la Vitamina A es seleccionado de retinoides, tretinoína, isotretinoína, etretinato, acitretina, tazaroteno, bexaroteno y adapaleno. Reivindicación 11: Una formulación tópica de acuerdo con la reivindicación 7, caracterizada en que dicho al menos un compuesto biológico es seleccionado de alefacept, atanercept, y anticuerpos monoclonales de adalimumab, infliximab, ustekinumab.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/076088 WO2014094840A1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094027A1 true AR094027A1 (es) | 2015-07-08 |
Family
ID=47520054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104757A AR094027A1 (es) | 2012-12-19 | 2013-12-16 | Formulaciones topicas que contienen pidotimod |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150328191A1 (es) |
| EP (1) | EP2934521B1 (es) |
| JP (1) | JP6051315B2 (es) |
| KR (1) | KR20150095773A (es) |
| CN (1) | CN104869994B (es) |
| AR (1) | AR094027A1 (es) |
| AU (1) | AU2012396942A1 (es) |
| BR (1) | BR112015011391A2 (es) |
| CA (1) | CA2887878A1 (es) |
| CY (1) | CY1118645T1 (es) |
| DK (1) | DK2934521T3 (es) |
| EA (1) | EA201591185A1 (es) |
| ES (1) | ES2617235T3 (es) |
| HK (1) | HK1210937A1 (es) |
| HR (1) | HRP20161666T1 (es) |
| HU (1) | HUE031846T2 (es) |
| IL (1) | IL239429A0 (es) |
| LT (1) | LT2934521T (es) |
| MA (1) | MA38155B1 (es) |
| ME (1) | ME02560B (es) |
| MX (1) | MX2015008104A (es) |
| PH (1) | PH12015501210A1 (es) |
| PL (1) | PL2934521T3 (es) |
| PT (1) | PT2934521T (es) |
| RS (1) | RS55436B1 (es) |
| SG (1) | SG11201503270UA (es) |
| SI (1) | SI2934521T1 (es) |
| SM (2) | SMT201700072T1 (es) |
| TN (1) | TN2015000142A1 (es) |
| WO (1) | WO2014094840A1 (es) |
| ZA (1) | ZA201502573B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (en) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod for use in the treatment of inflammation-associated diseases |
| MA44510A (fr) * | 2016-03-29 | 2021-03-31 | Janssen Biotech Inc | Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23 |
| CN105943505A (zh) * | 2016-05-26 | 2016-09-21 | 杭州百诚医药科技股份有限公司 | 一种匹多莫德药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2003018011A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase |
-
2012
- 2012-12-19 JP JP2015548221A patent/JP6051315B2/ja not_active Expired - Fee Related
- 2012-12-19 EA EA201591185A patent/EA201591185A1/ru unknown
- 2012-12-19 ES ES12812221.5T patent/ES2617235T3/es active Active
- 2012-12-19 CN CN201280076628.9A patent/CN104869994B/zh active Active
- 2012-12-19 US US14/652,482 patent/US20150328191A1/en not_active Abandoned
- 2012-12-19 HU HUE12812221A patent/HUE031846T2/hu unknown
- 2012-12-19 HR HRP20161666TT patent/HRP20161666T1/hr unknown
- 2012-12-19 SI SI201230870A patent/SI2934521T1/sl unknown
- 2012-12-19 BR BR112015011391A patent/BR112015011391A2/pt not_active IP Right Cessation
- 2012-12-19 PT PT128122215T patent/PT2934521T/pt unknown
- 2012-12-19 SM SM20170072T patent/SMT201700072T1/it unknown
- 2012-12-19 DK DK12812221.5T patent/DK2934521T3/en active
- 2012-12-19 LT LTEP12812221.5T patent/LT2934521T/lt unknown
- 2012-12-19 KR KR1020157018215A patent/KR20150095773A/ko not_active Withdrawn
- 2012-12-19 SG SG11201503270UA patent/SG11201503270UA/en unknown
- 2012-12-19 MX MX2015008104A patent/MX2015008104A/es unknown
- 2012-12-19 ME MEP-2016-277A patent/ME02560B/me unknown
- 2012-12-19 MA MA38155A patent/MA38155B1/fr unknown
- 2012-12-19 HK HK15111635.1A patent/HK1210937A1/xx unknown
- 2012-12-19 PL PL12812221T patent/PL2934521T3/pl unknown
- 2012-12-19 WO PCT/EP2012/076088 patent/WO2014094840A1/en not_active Ceased
- 2012-12-19 EP EP12812221.5A patent/EP2934521B1/en active Active
- 2012-12-19 CA CA2887878A patent/CA2887878A1/en not_active Abandoned
- 2012-12-19 AU AU2012396942A patent/AU2012396942A1/en not_active Abandoned
- 2012-12-19 RS RS20161102A patent/RS55436B1/sr unknown
-
2013
- 2013-12-16 AR ARP130104757A patent/AR094027A1/es unknown
-
2015
- 2015-04-14 TN TNP2015000142A patent/TN2015000142A1/fr unknown
- 2015-04-16 ZA ZA2015/02573A patent/ZA201502573B/en unknown
- 2015-05-29 PH PH12015501210A patent/PH12015501210A1/en unknown
- 2015-06-15 IL IL239429A patent/IL239429A0/en unknown
-
2017
- 2017-01-30 SM SM201700072T patent/SMT201700072B/it unknown
- 2017-02-21 CY CY20171100232T patent/CY1118645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014030820A2 (pt) | formulação de anticorpos | |
| CL2018001414A1 (es) | Anticuerpos contra cd73 y sus usos (divisional solicitud 201701296) | |
| MY166045A (en) | Abeta antibody formulation | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| AR085668A1 (es) | Terapias combinadas para malignidades hematologicas | |
| WO2012075319A3 (en) | Pharmaceutical cream compositions comprising oxymetazoline | |
| MX376804B (es) | Microcápsulas de núcleo/cubierta de capas múltiples. | |
| RU2013113188A (ru) | Комбинированное лечение дерматологических состояний | |
| PH12015502307A1 (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| AR102198A1 (es) | Proceso para reducir partículas subvisibles en una formulación farmacéutica | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| AR086231A1 (es) | Composicion util para el tratamiento de trastornos del metabolismo de lipidos | |
| BR112014014529A2 (pt) | métodos para melhorar terapias médicas | |
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| CR20180572A (es) | COMPOSICIONES PARASITICIDAS QUE COMPRENDEN UN AGENTE ACTIVO DE ISOXAZOLINA, SUS METODOS Y USOS (Divisional 2014-0117) | |
| CL2018000739A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma. | |
| BRPI0821145B8 (pt) | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido | |
| AR094027A1 (es) | Formulaciones topicas que contienen pidotimod | |
| JP2015523553A5 (es) | ||
| MX2017002610A (es) | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| PH12014501985A1 (en) | Il-17 antibody formulation | |
| BR112017007428A2 (pt) | composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |